Pfizer gets EC approval for Daurismo to treat newly diagnosed acute myeloid leukaemia

This article was originally published here

The approval has been granted for Daurismo, a Hedgehog pathway inhibitor, in combination with low-dose cytarabine (LDAC), a type of chemotherapy, to treat newly diagnosed AML in adult

The post Pfizer gets EC approval for Daurismo to treat newly diagnosed acute myeloid leukaemia appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply